Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer

[1]  Roland Eils,et al.  Tagmentation-based whole-genome bisulfite sequencing , 2013, Nature Protocols.

[2]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[3]  J. Huse,et al.  Evaluation of Histone 3 Lysine 27 Trimethylation (H3K27me3) and Enhancer of Zest 2 (EZH2) in Pediatric Glial and Glioneuronal Tumors Shows Decreased H3K27me3 in H3F3A K27M Mutant Glioblastomas , 2013, Brain pathology.

[4]  Dongfang Li,et al.  Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.

[5]  Gary D Bader,et al.  Computational approaches to identify functional genetic variants in cancer genomes , 2013, Nature Methods.

[6]  Laurence Amar,et al.  SDH mutations establish a hypermethylator phenotype in paraganglioma. , 2013, Cancer cell.

[7]  Michael Q. Zhang,et al.  Epigenomic Analysis of Multilineage Differentiation of Human Embryonic Stem Cells , 2013, Cell.

[8]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[9]  Fang Wang,et al.  An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells , 2013, Science.

[10]  Sabine Mueller,et al.  The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.

[11]  A. Ashworth,et al.  Histone H3.3. mutations drive pediatric glioblastoma through upregulation of MYCN. , 2013, Cancer discovery.

[12]  P. Jin,et al.  Genome-wide Profiling of 5-Formylcytosine Reveals Its Roles in Epigenetic Priming , 2013, Cell.

[13]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[14]  P. Meltzer,et al.  Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. , 2013, Cancer discovery.

[15]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[16]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[17]  R. Karchin,et al.  Collections of simultaneously altered genes as biomarkers of cancer cell drug response. , 2013, Cancer research.

[18]  Ryan S. Lee,et al.  Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer , 2013, Brain pathology.

[19]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[20]  C. Plass,et al.  Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. , 2013, Leukemia research.

[21]  Jonathan R. Pollack,et al.  The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers , 2013, PloS one.

[22]  Zhaohui S. Qin,et al.  Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. , 2013, Molecular cell.

[23]  Giovanni Parmigiani,et al.  Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma , 2012, Nature Genetics.

[24]  C. Roberts,et al.  ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.

[25]  Rochelle L. Tiedemann,et al.  Linking DNA methyltransferases to epigenetic marks and nucleosome structure genome-wide in human tumor cells. , 2012, Cell reports.

[26]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[27]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[28]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[29]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[30]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[31]  William A. Pastor,et al.  The anti-CMS technique for genome-wide mapping of 5-hydroxymethylcytosine , 2012, Nature Protocols.

[32]  William A. Pastor,et al.  The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine , 2012, Nature Protocols.

[33]  F. Bertucci,et al.  Mutations and deletions of ARID1A in breast tumors , 2012, Oncogene.

[34]  R. D. Hawkins,et al.  Methods for identifying higher-order chromatin structure. , 2012, Annual review of genomics and human genetics.

[35]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[36]  K. Cibulskis,et al.  Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.

[37]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[38]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[39]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[40]  M. Minden,et al.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Peter A. Jones,et al.  Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.

[42]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[43]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[44]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[45]  B. Bernstein,et al.  Genetic Events That Shape the Cancer Epigenome , 2012, Science.

[46]  Veronika Rockova,et al.  Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. , 2012, Blood.

[47]  G. Hon,et al.  Base-Resolution Analysis of 5-Hydroxymethylcytosine in the Mammalian Genome , 2012, Cell.

[48]  Svetlana Kotliarova,et al.  SnapShot: glioblastoma multiforme. , 2012, Cancer cell.

[49]  Andrew C. Adey,et al.  Ultra-low-input, tagmentation-based whole-genome bisulfite sequencing , 2012, Genome research.

[50]  Jinghui Zhang,et al.  Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.

[51]  Martin Dugas,et al.  Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia , 2012, Nature Medicine.

[52]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[53]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[54]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[55]  David T. W. Jones,et al.  Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations , 2012, Cell.

[56]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[57]  Mitchel S. Berger,et al.  Magnetic Resonance of 2-Hydroxyglutarate in IDH1-Mutated Low-Grade Gliomas , 2012, Science Translational Medicine.

[58]  Ovidiu C. Andronesi,et al.  Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy , 2012, Science Translational Medicine.

[59]  W. Sippl,et al.  Small Molecule Inhibitors of Histone Acetyltransferases as Epigenetic Tools and Drug Candidates , 2012, Archiv der Pharmazie.

[60]  Martin J. Aryee,et al.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer , 2011, Genome research.

[61]  J. Uhm.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[62]  Verena I Gaidzik,et al.  TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  P. Laird,et al.  Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina–associated domains , 2011, Nature Genetics.

[64]  E. Pronier,et al.  Role of TET2 Mutations in Myeloproliferative Neoplasms , 2012, Current Hematologic Malignancy Reports.

[65]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[66]  P. Pandolfi,et al.  In Vivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma , 2011, Cell.

[67]  Mazhar Adli,et al.  Whole-genome chromatin profiling from limited numbers of cells using nano-ChIP-seq , 2011, Nature Protocols.

[68]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[69]  C. Chung,et al.  Progress in the Discovery of Small-Molecule Inhibitors of Bromodomain–Histone Interactions , 2011, Journal of biomolecular screening.

[70]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[71]  Chuan He,et al.  Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.

[72]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[73]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[74]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[75]  I. Korf,et al.  Large-scale methylation domains mark a functional subset of neuronally expressed genes. , 2011, Genome research.

[76]  D. Patel,et al.  ATRX ADD domain links an atypical histone methylation recognition mechanism to human mental-retardation syndrome. , 2011, Nature structural & molecular biology.

[77]  C. Roberts,et al.  SWI/SNF nucleosome remodellers and cancer , 2011, Nature Reviews Cancer.

[78]  D. Higgs,et al.  Combinatorial readout of histone H3 modifications specifies localization of ATRX to heterochromatin , 2011, Nature Structural &Molecular Biology.

[79]  A. Feinberg,et al.  Increased methylation variation in epigenetic domains across cancer types , 2011, Nature Genetics.

[80]  M. Esteller,et al.  Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome , 2011, Epigenetics.

[81]  Emilia Dimitrova,et al.  The ATRX-ADD domain binds to H3 tail peptides and reads the combined methylation state of K4 and K9. , 2011, Human molecular genetics.

[82]  A. Bauer,et al.  Histone methylation by PRC2 is inhibited by active chromatin marks. , 2011, Molecular cell.

[83]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[85]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[86]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[87]  G. Crabtree,et al.  ATP-dependent chromatin remodeling: genetics, genomics and mechanisms , 2011, Cell Research.

[88]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[89]  Bin Wang,et al.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. , 2011, Cancer cell.

[90]  B. Zhu,et al.  H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation* , 2011, The Journal of Biological Chemistry.

[91]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[92]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[93]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[94]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[95]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[96]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[97]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[98]  C. Allis,et al.  New functions for an old variant: no substitute for histone H3.3. , 2010, Current opinion in genetics & development.

[99]  H. Scher,et al.  A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer , 2010, Cancer Chemotherapy and Pharmacology.

[100]  S. Rafii,et al.  Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions , 2010, Cell.

[101]  R. Hannan,et al.  ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. , 2010, Genome research.

[102]  P. Laird.  Principles and challenges of genome-wide DNA methylation analysis , 2010, Nature Reviews Genetics.

[103]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[104]  H. Haisma,et al.  Histone acetyl transferases as emerging drug targets. , 2009, Drug discovery today.

[105]  Jeffrey W. Scott,et al.  Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma , 2009, British journal of haematology.

[106]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[107]  Raymond K. Auerbach,et al.  Mapping accessible chromatin regions using Sono-Seq , 2009, Proceedings of the National Academy of Sciences.

[108]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[109]  B. Cairns,et al.  The biology of chromatin remodeling complexes. , 2009, Annual review of biochemistry.

[110]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[111]  B. Cairns,et al.  DNA Demethylation in Zebrafish Involves the Coupling of a Deaminase, a Glycosylase, and Gadd45 , 2008, Cell.

[112]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[113]  Xiaobo Xia,et al.  H3K79 methylation profiles define murine and human MLL-AF4 leukemias. , 2008, Cancer cell.

[114]  Amy E. Hawkins,et al.  DNA sequencing of a cytogenetically normal acute myeloid leukemia genome , 2008, Nature.

[115]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[116]  R. Durbin,et al.  A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis , 2008, Nature Biotechnology.

[117]  Ling Wang,et al.  The structural basis of protein acetylation by the p300/CBP transcriptional coactivator , 2008, Nature.

[118]  Scott A. Armstrong,et al.  MLL translocations, histone modifications and leukaemia stem-cell development , 2007, Nature Reviews Cancer.

[119]  Philip M. Kim,et al.  Paired-End Mapping Reveals Extensive Structural Variation in the Human Genome , 2007, Science.

[120]  N. Avvakumov,et al.  The MYST family of histone acetyltransferases and their intimate links to cancer , 2007, Oncogene.

[121]  K. Aldape,et al.  Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth , 2007, Proceedings of the National Academy of Sciences.

[122]  D. Weisenburger,et al.  Downregulation of Death-Associated Protein Kinase 1 (DAPK1) in Chronic Lymphocytic Leukemia , 2007, Cell.

[123]  Dustin E. Schones,et al.  High-Resolution Profiling of Histone Methylations in the Human Genome , 2007, Cell.

[124]  Sandya Liyanarachchi,et al.  Aberrant DNA Methylation of OLIG1, a Novel Prognostic Factor in Non-Small Cell Lung Cancer , 2007, PLoS medicine.

[125]  Christof Niehrs,et al.  Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation , 2007, Nature.

[126]  Kelly M. McGarvey,et al.  A stem cell–like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing , 2007, Nature Genetics.

[127]  Michael Rehli,et al.  Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia. , 2006, Cancer research.

[128]  James A. Cuff,et al.  A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells , 2006, Cell.

[129]  Wei Jiang,et al.  High-throughput DNA methylation profiling using universal bead arrays. , 2006, Genome research.

[130]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[131]  Christoph Plass,et al.  Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[132]  P. Fenaux.  Inhibitors of DNA methylation: beyond myelodysplastic syndromes , 2005, Nature Clinical Practice Oncology.

[133]  A. Gnirke,et al.  Reduced representation bisulfite sequencing for comparative high-resolution DNA methylation analysis , 2005, Nucleic acids research.

[134]  W. Lam,et al.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells , 2005, Nature Genetics.

[135]  T. Bestor,et al.  Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.

[136]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[137]  J. Byrd,et al.  Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. , 2005, Cancer research.

[138]  David Landsman,et al.  High-resolution genome-wide mapping of histone modifications , 2004, Nature Biotechnology.

[139]  B. Horsthemke,et al.  Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma , 1989, Human Genetics.

[140]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[141]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[142]  Colin C. Collins,et al.  Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors , 2002, Nature Genetics.

[143]  M. Esteller.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future , 2002, Oncogene.

[144]  S. Fröhling,et al.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[146]  W. Reik,et al.  Epigenetic Reprogramming in Mammalian Development , 2001, Science.

[147]  C Eng,et al.  Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. , 2001, Human molecular genetics.

[148]  C. Plass,et al.  Methylation matters , 2001, Journal of medical genetics.

[149]  R. Willemze,et al.  The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma , 2001, British journal of haematology.

[150]  M. Caligiuri,et al.  Aberrant CpG-island methylation has non-random and tumour-type–specific patterns , 2000, Nature Genetics.

[151]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[152]  J. Herman,et al.  CpG island methylator phenotype in colorectal cancer. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[153]  M. Caligiuri,et al.  Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene , 1999, Oncogene.

[154]  T. Huang,et al.  Methylation profiling of CpG islands in human breast cancer cells. , 1999, Human molecular genetics.

[155]  Olivier Delattre,et al.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.

[156]  M. Caligiuri,et al.  The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[157]  Y. Hayashizaki,et al.  New approach for detection of amplification in cancer DNA using restriction landmark genomic scanning. , 1992, Cancer research.

[158]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[159]  J. Rowley,et al.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[160]  S. Segawa,et al.  End of the beginning , 1990, Nature.

[161]  S. Baylin,et al.  DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas. , 1986, Cancer research.

[162]  C ASSANASEN,et al.  GLIOBLASTOMA MULTIFORME. , 1965, Virginia medical monthly.

[163]  Jeffry D Sander,et al.  FLAsH assembly of TALeNs for high-throughput genome editing , 2022 .